



PRELIMINAR VIRTUAL PROGRAM SCHEDULE

DAY 1 – Thursday 24th February

9:40 OPENING

Prof Rajiv Khanna, ISCT ANZ Vice President and **Dr Zlatibor Velickovic**, ISCT ANZ Vice President-Elect.

9:50 WELCOME

Dr Bruce Levine, ISCT President

9:55 GEOFF SYMONDS ORATION INTRODUCTION

A/Prof Robert Nordon, University of New South Wales, Sydney, Australia and **Dr Janet Macpherson**, Cytiva, Sydney, Australia

10:05 PLENARY SESSION

Dr Harry L. Malech, Chief, Genetic Immunotherapy Section, National Institute of Allergy and Infectious Diseases, National Institute of Health, Bethesda, USA.

11:00 MORNING BREAK

11:20 PRECLINICAL SESSION

Dr Rebecca Lim, Director of Scientific Affairs, Prescient Therapeutics, Melbourne, Australia.

Prof Michael Valenzuela, Co-Founder & Chief Scientist Skin2Neuron, Sydney, Australia.

Nathan Smith, Business Development Manager, Cell Therapies Pty Ltd, Melbourne, Australia.

Selected abstracts

13:00 LUNCH BREAK WITH EXHIBITORS

14:00 CLINICAL SESSION

A/Prof Professor Emily Blyth, Deputy Medical Director Sydney Cellular Therapies Laboratory, Department of Haematology, Westmead Hospital, Sydney, Australia.

A/Prof Professor Siok Tey, Department of Haematology and Bone Marrow Transplantation, Royal Brisbane and Women's Hospital, Medical Director, Q-Gen Cell Therapeutics, QIMR Berghofer, Brisbane, Australia.

Dr Ben Carnley, Medical Director, Cell and Tissue Therapies Western Australia, Royal Perth Hospital, Perth, Australia.

Selected abstracts

15:45 AFTERNOON BREAK



16:00 APPROVED CELL & GENE THERAPIES SESSION

TBC

DAY 2 – Friday 25th of February

10:00 REGULATORY SESSION – PRESENTATIONS

Dr Glenn Smith, Director, Biological Science Section, Scientific Evaluation Branch, Medicines Regulation Division, TGA Therapeutic Goods Administration, Canberra, Australia.

Peter Wenzel, Monitoring and Compliance, Office of the Gene Technology Regulator, Canberra, Australia.

Dr Tim Strabala, Principal Scientist, New Organisms, Hazardous Substances and New Organisms, Environmental Protection Authority, Wellington, New Zealand.

11:30 MORNING BREAK

11:50 REGULATORY SESSION – SCENARIOS DISCUSSION

Craig Wright, Royal Prince Alfred Hospital, Sydney, Australia

Gerry McKiernan, Cell Therapies, Melbourne Australia,

Dr Gabrielle O'Sullivan, Royal Prince Alfred Hospital, Sydney, Australia

Dr Giulia Giunti, Malaghan Institute of Medical Research, Wellington, New Zealand

Dr Glenn Smith, Director, Biological Science Section, Scientific Evaluation Branch, Medicines Regulation Division, TGA Therapeutic Goods Administration, Canberra, Australia.

Peter Wenzel, Monitoring and Compliance, Office of the Gene Technology Regulator, Canberra, Australia.

Dr Tim Strabala, Principal Scientist, New Organisms, Hazardous Substances and New Organisms, Environmental Protection Authority, Wellington, New Zealand.

13:30 LUNCH WITH EXHIBITORS

14:30 QUALITY WORKSHOP

A/Prof Ngaire Elwood, Director, BMDI Cord Blood Bank & Head, Cord Blood Stem Cell Research Program. Cell Biology, Murdoch Childrens Research Institute, Melbourne, Australia.

15:15 TRAINING WORKSHOP

TBC

16:00 AFTERNOON BREAK



16:20 COMMERCIALISATION PANEL

TBC

17:00 AWARDS
